ID

12769

Description

Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00385996

Link

https://clinicaltrials.gov/show/NCT00385996

Keywords

Versions (1)
  1. 12/21/15 12/21/15 -
Uploaded on

December 21, 2015

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Carcinoma, Non-small Cell Lung NCT00385996

English

Eligibility Carcinoma, Non-small Cell Lung NCT00385996

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
biopsy proven stage i/ii non-small cell lung cancer who are candidates for surgical resection
Description

Non-Small Cell Lung Carcinoma; Excision

Data type

boolean

Alias
UMLS CUI [1]
C0007131
UMLS CUI [2]
C0728940
ambulatory and capable of all self-care but may be unable to carry out any work activities.
Description

self-care; ambulatory

Data type

boolean

Alias
UMLS CUI [1]
C3639376
UMLS CUI [2]
C1550332
preoperative and postoperative high resolution ct scans done at nyph-weill cornell medical center for purposes of volumetric measurements.
Description

ct scans preoperative postoperative

Data type

boolean

Alias
UMLS CUI [1,1]
C0040405
UMLS CUI [1,2]
C0445204
UMLS CUI [1,3]
C0205903
acceptable cardiac, breathing, kidney, liver, and bone marrow functions.
Description

Cardiac function normal

Data type

boolean

Alias
UMLS CUI [1,1]
C0232164
UMLS CUI [1,2]
C0205307
18 years and older.
Description

age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
women of child-bearing potential must be taking adequate contraceptive precautions prior to study entry and for the duration of study participation. a negative serum or urine pregnancy test is required within 7-10 days of tarceva® administration. men and premenopausal women of child bearing potential will follow an approved, medically accepted birth control regimen or agree to abstain from heterosexual intercourse while taking study drug and for 30 days following the last dose of study drug.
Description

pregnancy; Contraceptive methods

Data type

boolean

Alias
UMLS CUI [1]
C0549206
UMLS CUI [2]
C0700589
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
cannot be on any other anti-cancer treatment during this study.
Description

Study Subject Participation Status

Data type

boolean

Alias
UMLS CUI [1]
C2348568
prior treatment with any egfr inhibitor.
Description

Epidermal growth factor receptor inhibitor

Data type

boolean

Alias
UMLS CUI [1]
C1443775
patients who had prior treatment with chemotherapy or radiation for this disease.
Description

chemotherapy; radiotherapy

Data type

boolean

Alias
UMLS CUI [1]
C0392920
UMLS CUI [2]
C0034619
other active cancers.
Description

active cancer

Data type

boolean

Alias
UMLS CUI [1]
C0006826
tumors with a mixed histology of small cell and non-small cell carcinoma as well as patients with pulmonary carcinoid tumors.
Description

comorbidity Lung Neoplasms

Data type

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0024121
gastro-intestinal abnormalities, including active peptic ulcer or inflammatory bowel disease.
Description

comorbidity Gastrointestinal Diseases

Data type

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0017178
hypersensitivity to compounds similar in chemical composition to tarceva®.
Description

hypersensitivity tarceva

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C1135136
active infection or serious underlying medical conditions which would impair protocol treatment.
Description

Compliance behavior limited comorbidity

Data type

boolean

Alias
UMLS CUI [1,1]
C1321605
UMLS CUI [1,2]
C0439801
UMLS CUI [1,3]
C0009488
Back to the top of the page

Similar models

Eligibility Carcinoma, Non-small Cell Lung NCT00385996

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Non-Small Cell Lung Carcinoma; Excision
Item
biopsy proven stage i/ii non-small cell lung cancer who are candidates for surgical resection
boolean
C0007131 (UMLS CUI [1])
C0728940 (UMLS CUI [2])
self-care; ambulatory
Item
ambulatory and capable of all self-care but may be unable to carry out any work activities.
boolean
C3639376 (UMLS CUI [1])
C1550332 (UMLS CUI [2])
ct scans preoperative postoperative
Item
preoperative and postoperative high resolution ct scans done at nyph-weill cornell medical center for purposes of volumetric measurements.
boolean
C0040405 (UMLS CUI [1,1])
C0445204 (UMLS CUI [1,2])
C0205903 (UMLS CUI [1,3])
Cardiac function normal
Item
acceptable cardiac, breathing, kidney, liver, and bone marrow functions.
boolean
C0232164 (UMLS CUI [1,1])
C0205307 (UMLS CUI [1,2])
age
Item
18 years and older.
boolean
C0001779 (UMLS CUI [1])
pregnancy; Contraceptive methods
Item
women of child-bearing potential must be taking adequate contraceptive precautions prior to study entry and for the duration of study participation. a negative serum or urine pregnancy test is required within 7-10 days of tarceva® administration. men and premenopausal women of child bearing potential will follow an approved, medically accepted birth control regimen or agree to abstain from heterosexual intercourse while taking study drug and for 30 days following the last dose of study drug.
boolean
C0549206 (UMLS CUI [1])
C0700589 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
Study Subject Participation Status
Item
cannot be on any other anti-cancer treatment during this study.
boolean
C2348568 (UMLS CUI [1])
Epidermal growth factor receptor inhibitor
Item
prior treatment with any egfr inhibitor.
boolean
C1443775 (UMLS CUI [1])
chemotherapy; radiotherapy
Item
patients who had prior treatment with chemotherapy or radiation for this disease.
boolean
C0392920 (UMLS CUI [1])
C0034619 (UMLS CUI [2])
active cancer
Item
other active cancers.
boolean
C0006826 (UMLS CUI [1])
comorbidity Lung Neoplasms
Item
tumors with a mixed histology of small cell and non-small cell carcinoma as well as patients with pulmonary carcinoid tumors.
boolean
C0009488 (UMLS CUI [1,1])
C0024121 (UMLS CUI [1,2])
comorbidity Gastrointestinal Diseases
Item
gastro-intestinal abnormalities, including active peptic ulcer or inflammatory bowel disease.
boolean
C0009488 (UMLS CUI [1,1])
C0017178 (UMLS CUI [1,2])
hypersensitivity tarceva
Item
hypersensitivity to compounds similar in chemical composition to tarceva®.
boolean
C0020517 (UMLS CUI [1,1])
C1135136 (UMLS CUI [1,2])
Compliance behavior limited comorbidity
Item
active infection or serious underlying medical conditions which would impair protocol treatment.
boolean
C1321605 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial